PT  - JOURNAL ARTICLE
AU  - Hannum, Mackenzie E.
AU  - Koch, Riley J.
AU  - Ramirez, Vicente A.
AU  - Marks, Sarah S.
AU  - Toskala, Aurora K.
AU  - Herriman, Riley D.
AU  - Lin, Cailu
AU  - Joseph, Paule V.
AU  - Reed, Danielle R.
TI  - Taste loss as a distinct symptom of COVID-19: A systematic review and meta-analysis
AID  - 10.1101/2021.10.09.21264771
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.09.21264771
4099  - http://medrxiv.org/content/early/2021/10/09/2021.10.09.21264771.short
4100  - http://medrxiv.org/content/early/2021/10/09/2021.10.09.21264771.full
AB  - Chemosensory scientists have been skeptical that reports of COVID-19 taste loss are genuine, in part because before COVID-19, taste loss was rare and often confused with smell loss. Therefore, to establish the predicted prevalence rate of taste loss in COVID-19 patients, we conducted a systematic review and meta-analysis of 376 papers published in 2020–2021, with 241 meeting all inclusion criteria. Additionally, we explored how methodological differences (direct vs. self-report measures) may affect these estimates. We hypothesized that direct prevalence measures of taste loss would be the most valid because they avoid the taste/smell confusion of self-report. The meta-analysis showed that, among 138,897 COVID-19-positive patients, 39.2% reported taste dysfunction (95% CI: 35.34–43.12%), and the prevalence estimates were slightly but not significantly higher from studies using direct (n = 18) versus self-report (n = 223) methodologies (Q = 0.57, df = 1, p = 0.45). Generally, males reported lower rates of taste loss than did females and taste loss was highest in middle-aged groups. Thus, taste loss is a bona fide symptom COVID-19, meriting further research into the most appropriate direct methods to measure it and its underlying mechanisms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. Mackenzie Hannum is supported by NIH T32 funding (DC000014). Dr. Joseph is supported by the National Institute of Alcohol Abuse and Alcoholism under award number, Z01AA000135 and the National Institute of Nursing Research, the NIH Office of Workforce Diversity, National Institutes of Health Distinguished Scholar, and the Rockefeller University Heilbrunn Nurse Scholar Award. Dr. Reed is supported in part through NIH U01DC019578.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript